Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1939 1
1941 1
1999 1
2007 1
2010 1
2012 2
2013 6
2014 10
2015 10
2016 12
2017 16
2018 31
2019 18
2020 1
2021 4
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31205999

86 results

Results by year

Filters applied: . Clear all
Page 1
Serum sickness-like reaction associated with mirabegron.
Tan MG, Burns BF, Glassman SJ. Tan MG, et al. JAAD Case Rep. 2019 Jun 8;5(6):537-539. doi: 10.1016/j.jdcr.2019.04.010. eCollection 2019 Jun. JAAD Case Rep. 2019. PMID: 31205999 Free PMC article. No abstract available.
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K. Yamaguchi O, et al. BJU Int. 2015 Oct;116(4):612-22. doi: 10.1111/bju.13068. Epub 2015 Apr 23. BJU Int. 2015. PMID: 25639296 Clinical Trial.
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER. Gratzke C, et al. Eur Urol. 2018 Oct;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1. Eur Urol. 2018. PMID: 29866467 Free article. Clinical Trial.
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR. Staskin D, et al. Int Urogynecol J. 2018 Feb;29(2):273-283. doi: 10.1007/s00192-017-3377-5. Epub 2017 Jun 15. Int Urogynecol J. 2018. PMID: 28620791 Free PMC article. Clinical Trial.
86 results